source
- Merck R&D chief says company has outpaced rivals with its sac-TMT cancer platformDean Li, the head of Merck Research Laboratories, said the company believes its sac-TMT cancer program gives it a competitive edge over other firms developing next-generation oncology therapies. T…
- Astellas secures exclusive option on Audax Biosciences preclinical IL-12 cancer drugAstellas has taken an exclusive option to license a preclinical immuno-oncology asset from Audax Biosciences, an Australian biotech company. The asset is an IL-12 based cancer therapeutic that is…